Michael K. Wang

NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era.

BACKGROUND Prior studies in the pre-MRI era suggest that patients with NCCN Intermediate and High Risk Grade Group 1 prostate cancer (GG1 PCa) on biopsy have increased risk for adverse oncologic outcomes. However, prostate MRI has altered patient selection for biopsy and improved prostate sampling. Herein, we examined...